The researchers identified significant problems in the Long-COVID study, including overly broad definitions and a lack of appropriate comparison groups, leading to distorted risks and consequences such as increased public anxiety and misdiagnosis, increased medical expenditures, frequent misdiagnoses, and misallocation of funds, among other problems in studies exploring the occurrence, frequency, and management of the disease.
They emphasized the need for better matched control groups and higher research standards, including more stringent definition criteria for Long-COVID, recommending replacing the term "Long-COVID" with a more specific term to accurately address different sequelae and improve outcomes.
Inclusion of substandard studies in systematic reviews and pooled data analyzes exacerbates this problem, further exaggerating risks, with possible consequences including, but not limited to: increased public anxiety and health care spending; misdiagnosis; and the diversion of funds away from those who actually develop other long-term illnesses secondary to COVID-19 infection.
Many of the sequelae of COVID-19 infection include post-ICU syndrome, a set of health problems that develop while patients are in the intensive care unit and persist after they are discharged home, and shortness of breath after pneumonia. Here's the thing: These are symptoms common to many upper respiratory viruses, researchers note.
Notably, the working definitions of "Long-COVID" used by influential health bodies such as the US Centers for Disease Control and Prevention, the World Health Organization, the UK's National Institute for Health and Care Excellence (NICE), the Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners do not require a causal link between the COVID-19 (SARS-CoV2) coronavirus and a range of symptoms, which comes with its own set of consequences.
The researchers say that not only should a reference (control) group be included in a "Long-COVID" study (which is usually not included), but the reference group should also be appropriately matched to the cases, preferably in terms of age, gender, geography, socioeconomic status, and, if possible, underlying health conditions and health behaviors, but the reference group is rarely matched.
In the early stages of the pandemic, SARS-CoV-2 testing was not widely available, so studies were more likely to include fewer SARS-CoV-2-positive patients with mild or asymptomatic symptoms, making the sample unrepresentative.
The researchers explain that this is known as sampling bias, which occurs when certain members of a population have a higher probability of being included in a study sample than others, potentially limiting the generalizability of the findings.
"Our analysis suggests that in addition to the inclusion of appropriately matched controls, better case definitions and more stringent ['Long-COVID'] criteria are needed, which should include persistent symptoms after confirmed SARS-CoV-2 infection and take into account baseline characteristics, including physical and mental health, that may influence an individual's post-COVID experience," they wrote. While results from high-quality population-based studies of "Long-COVID" in adults and children are reassuring, these studies are "rife with deeply biased studies," which list common pitfalls.
"Ultimately, biomedicine must seek to help all people affected by the disease. To do this, the best scientific methods and analyzes must be used. Inappropriate definitions and flawed methods do not serve the people medicine is meant to help. Raising the standards for evidence generation is an ideal way to take long-term COPD seriously, improve outcomes, and avoid the risks of misdiagnosis and inappropriate treatment."